Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $110M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | Red Tree V... | redtreevc.... |
| - | Hadean Ven... | hadeanvent... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.02.2021 | Series C | $80M | - |
| 18.12.2019 | Series B | $30M | - |
Mentions in press and media 15
Show more